45 results about "Immunomodulin" patented technology

The invention relates to application of recombined ganoderma lucidum immnoregulation protein (rLZ-8) in preparation of medicine for treating melanin tumor. In-situ tumor and metastatic tumor experiment animal models are used to research anti-tumor effect of rLZ-8, and the results show that the rLZ-8 can evidently inhibit in-situ tumor growing and metastasis forming of the melanin tumor.

The invention discloses a recombinant ganoderma lucidum immunoregulatory protein mutant and application thereof. The invention finds that an anti-EGFR structural domain exists in an rLZ-8 protein structure, and particularly an EGFR abnormal expression tumor killing effect is induced through the positive potential characteristic of the structural region. On the basis of the scientific discovery, the rLZ-8 mutant protein with a stronger anti-tumor effect is obtained by a computer simulation technology.

Provided are transmembrane immunomodulatory proteins, nucleic acids encoding such proteins and cells engineered with the proteins. The transmembrane immunomodulatory proteins and engineered cells provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided.

Provided are immunomodulatory proteins and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided.

The invention provides a novel application of a recombinant ganoderma lucidum immunological regulation protein (rLZ-8) in treating thrombopenia. In the experiments of preventing and treating the thrombopenia of rats and dogs caused by cyclophosphamide, the rLZ-8 prepared from physiological saline carries out administration on an experimental animal model with lower thrombocytes, THPO and IL-6 areused as positive medicines, continuous administration is carried out, the number of the thrombocytes in blood is detected, the changes of the number of the thrombocytes before and after therapy are contrasted, and the medicine effect is analyzed. Compared with a model group, the rLZ-8 medicine group already obviously stimulates the thrombocyte proliferation of rats, Guinea pigs and dogs in the initial period (the 3rd day to the 5th day) of the administration, the difference is very obvious, the thrombocytes are recovered to a normal level in the middle period (the 7th day to the 10th day) of the administration, and the invention also obtains a very good effect in treating the thrombopenia of a Guinea pig experimental animal model caused by injecting anti-thrombocyte serum.

The present invention relates to a method for treating a refractory or relapsed lung cancer. Particularly, the invention provides a method and a formulation of using an immunomodulatory protein derived from Ganoderma microsporum in the treatment of a refractory or relapsed lung cancer.

The invention relates to Favolus arcularius Ames immunomodulatory protein Fip-Par1 and a preparation method and application thereof. The amino acid sequence of the immunomodulatory protein is defined as SEQ ID NO.1. The preparation method comprises the steps: (1) connecting the cDNA sequence of the Favolus arcularius Ames immunomodulatory protein into a carrier, and obtaining a recombinant vector; (2) converting the recombinant vector to a host cell, and obtaining a recombination strain; (3) cultivating the recombination strain, inducing and recombining the expression of the Favolus arcularius Ames immunomodulatory protein Fip-Par1; and (4), obtaining through the NI column purification and the dialysis segregation. The immunomodulatory protein is used for preparing health food. The Favolus arcularius Ames immunomodulatory protein Fip-Par1 obtained by recombination in vitro is capable of remarkably promoting the immunomodulatory effects, such as spleen lymphocyte proliferation and expression of tumor necrosis factor TNF-a, and has application potential for improving the body immunity.

The present invention relates generally to the field of generating recombinant chimeric fusion proteins to be used in the cancer therapy, and more specifically, to fusion molecules of Anti-EGFR1-TGFβRII, Anti-EGFR1-PD1 and Anti-CTLA4-PD1 and methods of generating same, wherein the methods reduce production costs and increase homogeneity of the recombinant chimeric fusion proteins.